Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cyclooxygenase-2 (COX-2) plays a crucial role in cancer progression.
|
31473273 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
While previous studies have shown that the number of circulating tumor cells (CTCs) alone is not sufficient to reflect tumor progression and that cyclooxygenase-2 (COX-2) expression is correlated with colorectal cancer (CRC) metastasis, COX-2 expression status and its potential functions in CTCs of CRC patients are unknown.
|
30260024 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cross-talking between MAPK with oncogenic signaling pathways including WNT, cyclooxygenase-2, transforming growth factor-β, NOTCH and (in particular) with phosphatidylinositol 3-kinase is contributed to the multiplication of tumor progression and drug resistance.
|
31136035 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The cyclooxygenase-2 (COX-2) enzyme has been shown to increase in bladder cancer and has a direct relationship with tumor progression.
|
31443756 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase-2, COX-2)-prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) pathway promotes tumour progression.
|
30826660 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
TFAP2B bound to the promoter of COX-2 to activate its expression, indicating that TFAP2B is a critical regulatory molecule in the COX-2 signaling pathway that promoted tumor progression in thyroid cancer.
|
31113934 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The aim of our study; is to investigate the clinicopathological and the prognostic significance of SCF and COX-2 expression in prostatic adenocarcinoma (PC), chronic prostatitis and nodular prostatic hyperplasia (NPH) in a trial to clarify the role of inflammation as a risk factor for prostatic carcinogenesis and cancer progression.
|
30402808 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The positivity of p53 and COX-2 in a large proportion of BCCs, regardless of histological type and of depth of invasion, supports the two markers involvement in tumor progression.
|
30845292 |
2018 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
It was known that alterations in COX2 gene functions contribute to the inflammation process thus induce cancer progression, including cell proliferation, apoptosis, adhesion, invasion and metastasis.
|
30511628 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
COX‑2 inhibition in the endothelium induces glucose metabolism normalization and impairs tumor progression.
|
29257333 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Elevated cyclooxygenase-2 (COX-2) closely associates with tumor progression and distant metastasis in various human cancers.
|
29932878 |
2018 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The aim herein was to evaluate the Nintedanib therapeutic effects on morphology and COX-2 and IL-17 levels in the prostate anterior lobe in different grades of the tumor progression in TRAMP mice.
|
29429524 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
It is now recognized that COX-2 over expression promotes tumorigenic functions which can be suppressed by COX-2 inhibitors, a phenomenon useful for the preventing of tumor progression.
|
28971779 |
2018 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Consequently, the regenerative stimulus seems to be driven by a pro-inflammatory and hypoxic environment, in which M1 intrahepatic macrophages expressing COX-2 and T-Lymphocytes play a key role, facts which may be related with the tumor progression observed.
|
29795479 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We also found that the in vivo microenvironment enhanced activation of the COX-2 pathway, which further contributed to cancer progression.
|
29396430 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Significant correlations were observed with expression levels of key proteins involved in tumor progression and invasion namely E-cadherin and Cyclooxygenase-2.
|
29340045 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Gene expression analysis by microarray demonstrated that MDR1A deficiency shaped the inflammatory response towards an anti-tumorigenic microenvironment by downregulating genes known to be important mediators of cancer progression (PTGS2 (COX2), EREG, IL-11).
|
28686677 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
COX-2 is currently investigated as a major player of tumor progression in several type of malignancies including melanoma.
|
28231855 |
2017 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of EpCAM and COX‑2 was revealed to be associated with tumor progression, and poor prognosis in breast cancer.
|
28393249 |
2017 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, we found a correlation between H-ras expression and Cox-2 induction in OSCC tissue, suggesting that together these genes are contributing to cancer progression.
|
27628320 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The cyclooxygenase-2 (COX-2) inhibitor did not prevent cancer progression and did not affect the total number of macrophages in the tongues of 4NQO-treated mice.
|
28633143 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results point to a role for COX-2 in angiogenesis and in the establishment of an inflammatory microenvironment, favourable to melanoma tumour progression.
|
27105172 |
2016 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
MIR21 expression level in colorectal carcinoma is associated with worse clinical outcome, and this association is stronger in carcinomas expressing high-level PTGS2, suggesting complex roles of immunity and inflammation in tumor progression.
|
26957558 |
2016 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
COX-2 and its product PGE2 enhance carcinogenesis and tumor progression, which has been previously reported in melanoma.
|
26801201 |
2016 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To understand the role of COX-2 in tumor progression within a collagen-dense microenvironment, we treated MMTV-PyMT or MMTV-PyMT/Col1a1 (tm1jae) tumors prior to and after tumor formation.
|
27000374 |
2016 |